Toxic epidermal necrolysis as a complication of pembrolizumab treatment in a lung cancer patient. Issue 2 (9th December 2020)

• Record Type: Journal Article
• Authors: Aoyama, Reika; Kondo, Yukari; Azuma, Noriko; Kira, Masahiro
• Is Part Of: Journal of cutaneous immunology and allergy. Volume 4:Issue 2(2021)
• Page Start: 41
• Page End: 42
• Publication Date: 2020-12-09
• Subjects: Skin -- Diseases -- Immunological aspects -- Periodicals; Skin -- Diseases -- Periodicals; Skin -- Diseases -- Treatment -- Periodicals; 616.5079
• DOI: 10.1002/cia2.12150
• Languages: English
• ISSNs: 2574-4593

Abstract

Abstract : Cutaneous adverse events are common, but most of them are not severe. We herein report a case of toxic epidermal necrolysis as a complication of pembrolizumab treatment in a lung cancer patient. Recent reports showed that anti‐PD1 therapy could increase the risk of a drug eruption alone or in combination with other drugs. Cutaneous adverse events while on anti‐PD‐1 therapy should be closely observed.